Inclusion body myositis (IBM) is the most common progressive and debilitating muscle disease beginning in persons over 50 years of age. This study will assess the safety and tolerability of Arimoclomol in IBM as compared to placebo over four months of treatment.
Sponsor: Richard Barohn, MD
Link: http://clinicaltrials.gov/ct2/show/NCT00769860Year Trial Ends: 2017